Good afternoon :)
$
₹
Bio-Rad Laboratories Inc

Bio-Rad Laboratories Inc

BIO

NYSE
Asset Logo

Bio-Rad Laboratories Inc

BIO

NYSE
$370.081.81% (+6.58)
$
₹
$370.081.81% (+6.58)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Mid Cap

With a market cap of $9.6B the stock is ranked 1005

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

44.95
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.41
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$8.02
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.19
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

8.59%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
1 analyst
Hold
1 analyst
Sell
1 analyst

Price Upside

-9.45%

Earnings Growth

-4.74%

Rev. Growth

-0.53%

See Detailed Forecast

Company Profile

Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
36.60
36.60
1Y Return
17.81%
17.81%
Buy Reco %
85.71
85.71
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.11
34.11
1Y Return
17.92%
17.92%
Buy Reco %
68.18
68.18
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
34.64
34.64
1Y Return
27.03%
27.03%
Buy Reco %
86.36
86.36
Waters Corporation
WAT
Waters Corporation
P/E Ratio
112.12
112.12
1Y Return
27.55%
27.55%
Buy Reco %
75.00
75.00
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
52.77
52.77
1Y Return
169.5%
169.5%
Buy Reco %
52.38
52.38
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -9.45% growth, versus a trailing 3-year CAGR of 7.01%.

2026
Current$369.95Baseline
Analyst Target - 1 year
Target$335-9.45%

All values in $

202220232024202520262027$320.15$367.62$415.08Target-9.45%
2026
Current$369.95Baseline
Analyst Target - 1 year
Target$335-9.45%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -0.53% growth, versus a trailing 3-year CAGR of -2.68%.

2025
Current$2.58Baseline
Forecast for Dec 2026
High$2.59+0.43%
Average$2.56-0.53%
Low$2.53-2%

All values in $ Billion

2021202220232024202520262.922.802.672.562.58Low-2%Average-0.53%High+0.43%
2025
Current$2.58Baseline
Forecast for Dec 2026
High$2.59+0.43%
Average$2.56-0.53%
Low$2.53-2%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -4.74% growth, versus a trailing 3-year CAGR of -11.33%.

2025
Current$9.92Baseline
Forecast for Dec 2026
High$10.1+1.81%
Average$9.45-4.74%
Low$8.85-10.79%

All values in $

20212022202320242025202615.6714.2311.7710.319.92Low-10.79%Average-4.74%High+1.81%
2025
Current$9.92Baseline
Forecast for Dec 2026
High$10.1+1.81%
Average$9.45-4.74%
Low$8.85-10.79%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

653
-341.9
693.2
720
592.1
-527.1
651
371.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.610.630.640.660.580.650.650.690.590.65
Net Income0.38-2.160.65-0.710.060.31-0.340.72-0.520.37
Net Profit Margin62.85%-339.16%100.52%-107.23%10.93%48.77%-52.35%103.86%-89.02%57.05%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Bio-Rad Laboratories Inc 44.951.411.19
Thermo Fisher Scientific Inc36.604.661.98
Agilent Technologies Inc34.116.331.36
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BIO with any stock or ETF
Compare BIO with any stock or ETF
Comparing from
BIO
TMO
A
Loading...

Frequently asked questions

  1. Bio-Rad Laboratories Inc (BIO) share price today is $370.08 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $371.13 and a day low of $355.59.

  2. Bio-Rad Laboratories Inc stock trades on NYSE under the ticker symbol BIO.

  3. Bio-Rad Laboratories Inc's market capitalization is $9.63B as of October 24, 2026 at 1:29 AM IST.

  4. Bio-Rad Laboratories Inc's price-to-earnings (P/E) ratio is 44.95 as of October 23, 2026.

  5. Bio-Rad Laboratories Inc's price-to-book (P/B) ratio is 1.41 as of October 23, 2026.

  6. Yes, You can buy Bio-Rad Laboratories Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Bio-Rad Laboratories Inc shares in three steps: 1. Search Bio-Rad Laboratories Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Bio-Rad Laboratories Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Bio-Rad Laboratories Inc (BIO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.027 shares at the current price of $370.08.

Loading...